Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Jean S Beebe"'
1
Akademický článek
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
Autor: Spencer I. Danto, Nikolaos Tsamandouras, Padma Reddy, Steven A. Gilbert, Jessica Y. Mancuso, Karen Page, Jean S. Beebe, Elena Peeva, Michael S. Vincent
Publikováno v: Allergy, Asthma & Clinical Immunology, Vol 20, Iss 1, Pp 1-8 (2024)
Abstract PF-06817024 is a humanized antibody against interleukin-33 that has the potential to inhibit type 2 inflammation. An exploratory analysis of the pharmacodynamics and clinical effects of single and repeat doses of PF-06817024 was assessed in
Externí odkaz: https://doaj.org/article/342daf6733c54dea9222dbbb5a9d74c3
Zobrazit plný text záznamu
2
Akademický článek
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Autor: Stanley Cohen, Jean S. Beebe, Vishala Chindalore, Shunjie Guan, Mina Hassan-Zahraee, Madhurima Saxena, Li Xi, Craig Hyde, Sarita Koride, Robert Levin, Shannon Lubaczewski, Mikhail Salganik, Abigail Sloan, Erin Stevens, Elena Peeva, Michael S. Vincent, David A. Martin, Myron Chu
Publikováno v: Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-18 (2024)
Abstract Background The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5
Externí odkaz: https://doaj.org/article/de4e6e08230342d8a8ccd262c81c4143
Zobrazit plný text záznamu
3
Akademický článek
Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial
Autor: Emma E. Davenport, Tiffany Amariuta, Maria Gutierrez-Arcelus, Kamil Slowikowski, Harm-Jan Westra, Yang Luo, Ciyue Shen, Deepak A. Rao, Ying Zhang, Stephen Pearson, David von Schack, Jean S. Beebe, Nan Bing, Sally John, Michael S. Vincent, Baohong Zhang, Soumya Raychaudhuri
Publikováno v: Genome Biology, Vol 19, Iss 1, Pp 1-15 (2018)
Abstract Background Cytokines are critical to human disease and are attractive therapeutic targets given their widespread influence on gene regulation and transcription. Defining the downstream regulatory mechanisms influenced by cytokines is central
Externí odkaz: https://doaj.org/article/8075e72d26c1477fb0d4a12d32759788
Zobrazit plný text záznamu
5
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
Autor: Megan N Landis, Stacy R Smith, Gabriel Berstein, Gerald Fetterly, Pranab Ghosh, Gang Feng, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S Vincent, Jean S Beebe, Sanela Tarabar
Publikováno v: British Journal of Dermatology.
Background Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways. Objectives To assess the efficacy and safety of multiple doses of topical brepocitinib, a tyrosine kinase
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c050877b4031a6cf8082f8c53d27a09
https://doi.org/10.1093/bjd/ljad098
Zobrazit plný text záznamu
7
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study
Autor: Megan N. Landis, Mark Arya, Stacy Smith, Zoe Draelos, Lisa Usdan, Sanela Tarabar, Vivek Pradhan, Sudeepta Aggarwal, Christopher Banfield, Elena Peeva, Michael S. Vincent, Vanja Sikirica, Jason Xenakis, Jean S. Beebe
Publikováno v: The British journal of dermatologyReferences. 187(6)
Background Atopic dermatitis (AD) is a prevalent inflammatory, pruritic skin disease. The Janus kinase (JAK) pathway is a treatment target. Objectives To assess the efficacy, safety and pharmacokinetics of topical cream brepocitinib, a small-molecule
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cef62276a1c4d898f2ddd859b40f148
https://pubmed.ncbi.nlm.nih.gov/36199210
Zobrazit plný text záznamu
8
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Autor: Zorayr Manukyan, Deepa E. Chandra, Alan Kivitz, Michael Saunders, Christopher Banfield, Jean S. Beebe, Bojana Stamenkovic, Jessica Mancuso, Elena Peeva, Michael S. Vincent, Michael F. Robinson, Nemanja Damjanov, Lori Ann Cox, Goran Radunovic
Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)
Objective To evaluate the efficacy and safety of PF‐06651600 (ritlecitinib), an irreversible inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, in comparison with placebo in patients with rheumatoid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::080958e646c9ba5b2dfaf77a1f17b14e
https://doi.org/10.1002/art.41316
Zobrazit plný text záznamu
9
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a
Autor: Ravi Shankar P, Singh, Martin E, Dowty, Mikhail, Salganik, Joanne I, Brodfuehrer, Gregory S, Walker, Raman, Sharma, Jean S, Beebe, Spencer I, Danto
Publikováno v: Clinical pharmacology in drug development. 11(7)
Zimlovisertib (PF-06650833) is a selective, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) with anti-inflammatory effects. This phase 1, open-label, fixed-sequence, two-period, single-dose study aimed to evaluate the mass
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7cd46b4e9d3fec435f9829db31ea9edb
https://pubmed.ncbi.nlm.nih.gov/35506501
Zobrazit plný text záznamu
10
Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease
Autor: Satoshi Shoji, Cheryl Li, Jean S. Beebe
Publikováno v: British Journal of Clinical Pharmacology. 84:2059-2074
Aims The purpose of this study was to characterize pharmacokinetics (PK) of PF-04236921, a novel anti-interleukin-6 monoclonal antibody, and its pharmacokinetic/pharmacodynamic (PK/PD) relationship on serum C-reactive protein (CRP) in healthy volunte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd3b422bd42937d688978b418234243d
https://doi.org/10.1111/bcp.13641
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje